Research Pulse — 2026-08-13 | Brown Biotech

# Research Pulse — 2026-08-13
_Generated 2026-08-13 07:32 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 8월 13일 (목요일) · Catalyzing(Catalyzing Day)**

8/13(Catalyzing)→8/12(Consolidating)→8/11(Integrating)→8/10(Translating)→8/9(Converging)→8/8→8/7(Transcribing)→8/6(Industrializing)→8/5(Maturing)→8/4(Verifying)→8/3→...→7/14(가속). Consolidating(8/12)된 기술들이 **이전 단계들의 축적된 결과를 다음 단계의 연쇄 반응(Chain Reaction)을 Catalyzing하는 날** — Cerebrovascular cell atlas가 뇌혈관 314,535 transcriptome + spatial mapping으로 뇌질환 연구 표준 catalyst 확인(Wang Cell 2026), ALDH9A1-carnitine axis가 NSCLC anti-PD-1 resistance mechanism의 multi-omics(CODEX+metabolomics+CyTOF+ATAC-seq+spatial transcriptomics) 완전 통합으로 resistance突破의 catalyst 확인(Du PNAS 2026), Cervical cancer spatial omics이 macrophage-T-cell crosstalk을 spatial immune niche 모델로 재정의하여 면역저항성 돌파의 catalyst 확인(Huang Frontiers Immunology 2026), Prime editing PE7 + nanoCas delivery가 in vivo 전달 기술의 체계를 넘어 actual therapeutic applications로의 연쇄 반응을催化 확인(Jong BMB Reports 2026 + Hossain Molecular Biotechnology 2026), AI competitive docking이 pairwise ranking으로 virtual screening의 practical catalyst 확인(Mirgaux npj Drug Discovery 2026), Livestock multi-omics integration framework이 livestock-specific causal inference 체계로 precision breeding의 catalyst 확인(Wen Advanced Science 2026)이 동시에 진행된다.

Catalyzing은 Consolidating의 다음 단계다. 오늘 6개 전선은 Consolidated된 기술들이 서로를 catalyst로 삼아 다음 단계의 연쇄 반응을 시작하는 날이다.

*출처: [Wang Cerebrovascular Cell Atlas Cell 2026](https://consensus.app/papers/details/96e627a4cb495033b5aad44ee8b6cffa/), [Du ALDH9A1 NSCLC PNAS 2026](https://consensus.app/papers/details/96e627a4cb495033b5aad44ee8b6cffa/), [Huang Cervical Cancer Spatial Immune Frontiers Immunology 2026](https://consensus.app/papers/details/96e627a4cb495033b5aad44ee8b6cffa/), [Jong Prime Editing Updates BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/), [Hossain CRISPR NanoCas Cancer Molecular Biotechnology 2026](https://consensus.app/papers/details/9d5090d89fcc57f989ef3d82ec5d090a/), [Mirgaux AI Competitive Docking npj Drug Discovery 2026](https://consensus.app/papers/details/645fe54721bb5cb8b226c81c539960bc/), [Wen Livestock Multi-Omics Advanced Science 2026](https://consensus.app/papers/details/96e627a4cb495033b5aad44ee8b6cffa/)*

*#CatalyzingDay #CerebrovascularAtlas #Wang #Cell2026 #ALDH9A1 #NSCLC #Du #PNAS #CervicalCancer #SpatialOmics #Huang #FrontiersImmunology #PrimeEditing #Jong #BMBReports2026 #NanoCas #Hossain #CompetitiveDocking #Mirgaux #LivestockMultiOmics #Wen #Catalyzing #Consolidation #ChainReaction #SpatialTranscriptomics #BrainVasculature #ImmunotherapyResistance*

---

### Post 2: 뇌혈관세포 Atlas — 뇌혈관 314,535 transcriptome + Spatial Mapping으로 뇌질환 연구 표준 Catc

🧠 **[Spatial Transcriptomics / Brain] 뇌혈관세포 Atlas가 314,535 transcriptome + spatial mapping으로 뇌혈관 아킬텍처의 공간적·기능적 표준을 Catalyzing 확인(Wang Cell 2026) — 뇌혈관 specialized cell ensembles의 공간적 조직 규명 + 유전적 위험도·약리학적 반응도 overlay로 neurological disease 치료 타겟 발견의 표준 catalyst:**

뇌혈관세포 Atlas의 **공간적·기능적 통합 표준(Catalyzing)**이 Wang et al.(Cell 2026)에서 확인된다[1].

**Cerebrovascular Cell Atlas: 공간적·기능적 통합 표준 Catalyzing[1]**
Jerry C. Wang et al.(Cell 2026)의 연구는 뇌혈관세포 atlas를 구축한다. **314,535 transcriptome으로 arteriovenous axis 정의 + consensus cell states 규명** — 인간 temporal cortex + hippocampus에서 **1,529,740 cells spatial transcriptomics mapping** 수행. **Vascular cell ensembles(VCEs)** 발견: endothelial cells, mural cells, fibroblasts, perivascular macrophages의 specialized subsets이 arteriovenous architecture에 맞춰 배열. **Segment-specific 기능 좌표确定**: neurovascular coupling, blood-brain barrier transport, immune surveillance. **유전적 위험도 + 약리학적 반응도 overlay**로 neurological diseases(small vessel disease, stroke)에 대한 **ensemble-specific susceptibilities + candidate therapeutic targets** 식별. 뇌혈관 아킬텍처의 공간적·기능적 표준을Catalyzing하여 뇌질환 연구의 새로운 표준 catalyst로 자리매김.

**기존 Consolidating(8/12)과의 차별점**: 8/12의 LVNPs Consolidating이 비바이러스성 전달 산업화 체계의 Consolidating에 집중했다면, 오늘은 **뇌혈관이라는 특정 장기·조직의 공간적 세포 아킬텍처를 atlas 수준에서 Catalyzing**하는 것으로, 질병 특이적 spatial atlas의 산업 표준화를 의미한다.

실무 함의: 뇌혈관연구팀에서 Wang et al.의 VCEs framework를 분석하여 small vessel disease + stroke 치료 타겟 discovery pipeline을 수립해야 한다.

*출처: [Wang Cerebrovascular Cell Atlas Cell 2026](https://www.cell.com/cell/abstract/S0092-8674(26)00805-6)*

*#CerebrovascularAtlas #BrainVasculature #SpatialTranscriptomics #Cell2026 #Wang #NeurovascularCoupling #BloodBrainBarrier #SmallVesselDisease #Stroke #VascularCellEnsembles #CatalyzingDay #AtlasStandard #Neurodegeneration #TherapeuticTargets*

---

### Post 3: ALDH9A1-Carnitine Axis — NSCLC multi-omics 통합으로 Anti-PD-1 Resistance 메커니즘의 돌파구 Catalyzing

🫁 **[Single-cell Multi-omics] ALDH9A1-carnitine signaling axis가 NSCLC anti-PD-1 resistance mechanism을 multi-omics(CODEX+metabolomics+CyTOF+ATAC-seq+spatial transcriptomics) 완전 통합으로 돌파하는 catalyst 확인(Du PNAS 2026) — ALDH9A1 carnitine production → acetyl-CoA ↑ → Il1b superenhancer 활성화 → MDSC polarization + CD8 T cell exhaustion:**

NSCLC immunotherapy resistance의 **multi-omics 완전 통합 돌파구**가 Du et al.(PNAS 2026)에서 확인된다[2].

**ALDH9A1 Multi-omics Mechanism: Immunotherapy Resistance 돌파 catalyst[2]**
Hailei Du et al.(PNAS 2026)의 연구는 NSCLC에서 ALDH9A1-carnitine axis의 immunotherapy resistance mechanism을 multi-omics로 규명한다. **Integrating CODEX + metabolomics + CyTOF + ATAC-seq + single-cell spatial transcriptomics**으로 전체 면역환경을 mapping. **ALDH9A1 carnitine production → acetyl-CoA levels elevated → chromatin accessibility 변화 → Il1b superenhancer 활성화** 메커니즘 확인. **MDSC(Myeloid-derived suppressor cells) polarization 촉진 + CD8 T cell exhaustion 유발**. **IL-1β → NF-κB → ALDH9A1 상승**의 **positive feedback loop** 확인. In vivo에서 **genetic/pharmacological ALDH9A1 억제 또는 IL-1β 중화항체**가 anti-PD-1 therapy 민감성 회복. **ALDH9A1/IL-1β axis가 NSCLC 환자에서 빈번하게 hyperactivated + anti-PD-1 반응열등과 상관관계** 확인. Immunotherapy resistance 메커니즘의 완전 통합 규명으로 resistance 돌파의 표준 catalyst로 자리매김.

**8월 11일 Integration Day vs 오늘의 차별점**: 8/11의 integration이 **multi-omics+AI의 end-to-end 통합(Liu Signal Transduction Targeted Therapy 2026)**에 집중했다면, 오늘은 **NSCLC라는 특정 적응증에서 ALDH9A1-carnitine axis라는 구체적 메커니즘을 multi-omics로 완전 규명**하여 임상적 돌파구를 제시한다. Integration(8/11) → 특정 암종 특정 메커니즘의 Catalyzing(8/13).

실무 함의: 면역항암제 연구팀에서 ALDH9A1 억제제 + anti-PD-1 병용 치료 전략의 임상 가능성을 평가해야 한다.

*출처: [Du ALDH9A1 NSCLC Immunotherapy Resistance PNAS 2026](https://www.pnas.org/doi/10.1073/pnas.2535328123)*

*#ALDH9A1 #NSCLC #ImmunotherapyResistance #PD1 #Carnitine #MultiOmics #CODEX #CyTOF #SpatialTranscriptomics #Du #PNAS2026 #MDSC #CD8T #IL1Beta #FeedbackLoop #CatalyzingDay #PrecisionOncology #MetabolicReprogramming #ChromatinAccessibility #SuperEnhancer*

---

### Post 4: Cervical Cancer Spatial Immunity — HPV-Driven Immune Tolerance의 Spatial Immune Niche 모델 재정의

🧫 **[Spatial Transcriptomics / Cancer] Cervical cancer spatial omics이 macrophage-T-cell crosstalk을 spatial immune niche 모델로 재정의하여 면역저항성 돌파 전략의 catalyst 확인(Huang Frontiers Immunology 2026) — SPP1/C1QC macrophage states + HPV continuous programming + cGAS-STING circuits:**

Cervical cancer 면역 미세환경의 **spatial immune niche 모델**이 Huang et al.(Frontiers Immunology 2026)에서 확인된다[3].

**Cervical Cancer Spatial Immune Niche: 면역저항성 catalyst[3]**
Li Huang et al.(Frontiers Immunology 2026)의 review는 cervical cancer에서 **spatial immune niche 모델**을 제시한다. **기존 paradigm의 한계**: binary M1/M2 macrophage polarization + checkpoint expression만으로 T-cell dysfunction 해석 부족. **새로운 paradigm**: **SPP1 macrophage + C1QC macrophage states**라는 highly-resolved myeloid programs 식별. 이 프로그램들이 **stromal barriers, regulatory T cells, metabolic checkpoints**와 상호작용하여 **effector T cells를 suppressive niches 내에 가둠**. **HPV가 단순 carcinogenic trigger가 아닌 continuous programmer**: **cGAS-STING related circuits를 rewiring하여 local immune tolerance를 질병全过程에서 안정화**. Multi-omic atlases를 **pathology-compatible prognostic + predictive biomarker signatures**로 전환하는 translational strategy 제시. Cervical cancer 면역저항성의 spatial organization을 규명하여 면역疗법 돌파구의 catalyst로 자리매김.

**8월 11일 Spatial Ecotypes(Zhang Nature 2026) vs 오늘의 차별점**: 8/11의 Zhang et al.이 **spatial ecotypes를 cfDNA liquid biopsy로 비침습적 모니터링**에 집중했다면, 오늘의 Huang et al.은 **cervical cancer라는 특정 암종에서 HPV-driven continuous immune tolerance mechanism**을 spatial niche 모델로 재정의한다. Same spatial technology → 다른 적응증, 다른 메커니즘, 같은 Catalyzing 방향.

실무 함의: 부인암 연구팀에서 SPP1/C1QC macrophage targeting 전략과 HPV-cGAS-STING circuit 억제 전략의 병용 가능성을 탐색해야 한다.

*출처: [Huang Cervical Cancer Spatial Immune Niche Frontiers Immunology 2026](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1896004/full)*

*#CervicalCancer #SpatialOmics #MacrophageTCrosstalk #Huang #FrontiersImmunology #HPV #SPP1Macrophage #C1QC #cGASSTING #ImmuneTolerance #TumorMicroenvironment #SpatialNiche #CatalyzingDay #ImmunotherapyResistance #Biomarker #TranslationalStrategy*

---

### Post 5: Prime Editing PE7 + NanoCas — In Vivo 전달 기술의 연쇄 반응(Catalyzing) 확인

🧬 **[CRISPR/Gene Editing] Prime editing PE7 updates + nanoCas delivery systems이 기존 LVNPs Consolidating(8/12)을 넘어 in vivo therapeutic applications의 연쇄 반응을 Catalyzing 확인(Jong BMB Reports 2026 + Hossain Molecular Biotechnology 2026) — PE1→PE7 efficiency进化 + nanoCas compact delivery advantages:**

CRISPR 전달 기술의 **下一代 연쇄 반응(Catalyzing)**이 두 출처에서 동시에 확인된다[4][5].

**Prime Editing PE7 Updates: Delivery Strategies for In Vivo Applications[4]**
U. Jong et al.(BMB Reports 2026)의 review는 prime editing의 technological evolution을 분석한다. **PE1→PE7까지 efficiency 향상 + editable target range 확장 + large genomic region correction + in vivo delivery technologies 발전**. Prime editing이 **double-strand breaks 없이 precise base substitutions, insertions, deletions** 가능. **Cas9 nickase + reverse transcriptase fusion protein + pegRNA** 작동 원리. **In vivo delivery platforms**: viral vectors(AAV의 cargo capacity 제한, immunogenicity 문제) + non-viral platforms(LNPs의 up to 93% protein knockdown 확인). Prime editing의 기술적进化이 therapeutic applications로의 연쇄 반응을催化.

**NanoCas for Cancer Treatment: Compact Delivery Advantages[5]**
Hemayet Hossain et al.(Molecular Biotechnology 2026)의 review는 nanoCas systems의 암治疗 적용을 분석한다. **NanoCas: compact Cas orthologs에서 파생된 소형 Cas 시스템** — in vivo applications에 유망한 delivery advantages 제공. **CRISPR-Cas9, base editing, prime editing, nanoCas 비교**: 각 플랫폼의 molecular mechanisms, delivery challenges, oncological applications, clinical prospects 정리. **NanoCas delivery advantages가 기존 large Cas systems의 한계를 극복**하여 암治疗용 genome editing의 다음 단계 catalyst로 확인.

**8월 12일 LVNPs Consolidating vs 오늘의 차별점**: 8/12의 Consolidating이 **LVNPs라는 특정 비바이러스성 전달 체계**에 집중했다면, 오늘은 **prime editing 전체 PE1→PE7进化 timeline + nanoCas라는 새로운 대체 전달 기술**을 동시에 제시하여 CRISPR 전달 기술 전반의 연쇄 반응을 Catalyzing한다. Consolidating(8/12) → Delivery technology 다양화 Catalyzing(8/13).

실무 함의: 基因치료 전달기술팀에서 nanoCas의 compact delivery advantages와 PE7의 large genomic region correction 능력을 combined delivery strategy로 평가해야 한다.

*출처: [Jong Prime Editing PE7 In Vivo Delivery BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/), [Hossain NanoCas Cancer Treatment Molecular Biotechnology 2026](https://consensus.app/papers/details/9d5090d89fcc57f989ef3d82ec5d090a/)*

*#PrimeEditing #PE7 #NanoCas #Jong #BMBReports2026 #Hossain #MolecularBiotechnology2026 #InVivoDelivery #CRISPR #BaseEditing #GeneTherapy #DeliveryTechnology #CatalyzingDay #CompactCas #Oncology #AAV #LNP #TumorMicroenvironment #TherapeuticApplications*

---

### Post 6: AI Competitive Docking — Pairwise Ranking으로 Virtual Screening의 Practical Catalyst 확인

💊 **[AI Drug Discovery] AI-guided competitive docking이 pairwise ranking으로 AlphaFold3/Boltz-2의 practical drug discovery catalyst 확인(Mirgaux npj Drug Discovery 2026) — 17 protein benchmark에서 concordance 0.52~0.89 + BTK kinase covalent inhibitor de novo design:**

AI-driven drug discovery의 **practical catalyst**가 Mirgaux et al.(npj Drug Discovery 2026)에서 확인된다[6].

**AI Competitive Docking: Pairwise Ranking으로 Practical Catalyst[6]**
M. Mirgaux et al.(npj Drug Discovery 2026)의 연구는 **pairwise competitive docking** 전략을 제시한다. **Denoise diffusion-based co-folding methods(AlphaFold3, Boltz-1/2)**의 practical drug discovery 적용 확인. **Pairwise competitive docking**: 두 분자의 상대적 binding을 직접 비교하여 candidate molecules를 ranking. **17 protein benchmark systems에서 concordance indices 0.52~0.89** — 시스템에 따라 상관관계 수준 차이 있으나 전반적 experimental trends와 일치. **Boltz-2 affinity predictions와 strong agreement** — inhibitor prioritization을 위한 practical alternative로 확인. **Large chemical library에서 promising hits 식별 속도 가속 + de novo design of improved potency inhibitors** 가능. 구조기반 약물설계의 practical catalyst로 자리매김.

**8월 9일 Convergence Day(Feldman adversarial mutations) vs 오늘의 차별점**: 8/9의 Convergence가 **AlphaFold3 adversarial mutations의 한계 정량화**(40% 잔기 치환에도 구조 불변)에 집중했다면, 오늘은 **AlphaFold3/Boltz-2의 한계를 보완하는 practical workaround(pairwise competitive docking)**를 제시한다. Adversarial limitations(8/9) → Practical solutions Catalyzing(8/13).

실무 함의: 약물탐색팀에서 Mirgaux et al.의 pairwise competitive docking protocol을 virtual screening workflow에 통합하여 hits identification 속도를 높여야 한다.

*출처: [Mirgaux AI Competitive Docking npj Drug Discovery 2026](https://consensus.app/papers/details/645fe54721bb5cb8b226c81c539960bc/)*

*#CompetitiveDocking #VirtualScreening #Mirgaux #npjDrugDiscovery2026 #AlphaFold3 #Boltz2 #PairwiseRanking #DeNovoDesign #BTK #Kinase #Inhibitor #CatalyzingDay #AI #DrugDiscovery #ProteinStructure #DenoisingDiffusion #PracticalCatalyst #HitsIdentification*

---

### Post 7: Livestock Multi-Omics Framework — Livestock-Specific Causal Inference 체계로 Precision Breeding Catalyst

🐄 **[Single-cell Multi-omics Foundation Model] Livestock multi-omics integration이 livestock-specific causal inference framework로 precision breeding의 catalyst 확인(Wen Advanced Science 2026) — extreme species diversity, data heterogeneity, small sample sizes의 한계를 three-tier framework로 극복:**

Livestock 연구 영역의 **multi-omics 통합 framework**가 Wen et al.(Advanced Science 2026)에서 확인된다[7].

**Livestock Multi-Omics Integration: Causal Inference Framework Catalyst[7]**
Jiying Wen et al.(Advanced Science 2026)의 review는 livestock multi-omics integration의 체계적 framework를 제시한다. **Four common pitfalls 식별**: (1) correlation을 causation으로 overinterpreting, (2) proteomics를 transcriptomics의 corroborating으로 relegated, (3) incomplete microbiome-host integration, (4) metabolic fluxomics의 systematic neglect. **Three-tier analytical framework 제시**: (1) statistical association of cross-omics covariation patterns, (2) ML-driven feature mining + integrative modeling, (3) causal interpretation(Mendelian randomization + prior-knowledge-guided network inference + fluxomics). **Generative AI + multimodal sequencing(single-cell, spatial, temporal)**이 heterogeneity를 완화하고 causal evidence를 강화. Database standardization + livestock-specific benchmarking + translational pipelines의 future priorities 제시. Livestock-specific causal inference 체계로 precision breeding의 catalyst로 자리매김.

**8월 11일 Integration Day(scGPT, SCMBench) vs 오늘의 차별점**: 8/11의 Integration이 **scGPT foundation model + SCMBench benchmarking**에 집중했다면, 오늘은 **livestock라는 특정 도메인에서 multi-omics 통합의 practical framework**를 제시한다. General foundation model benchmarking(8/11) → Domain-specific causal inference framework Catalyzing(8/13).

실무 함의: 동물유전체학팀에서 Wen et al.의 three-tier framework를 livestock breeding program에 적용하여 causal inference 기반品種改善을 추진해야 한다.

*출처: [Wen Livestock Multi-Omics Integration Advanced Science 2026](https://consensus.app/papers/details/96e627a4cb495033b5aad44ee8b6cffa/)*

*#LivestockMultiOmics #Wen #AdvancedScience2026 #PrecisionBreeding #CausalInference #MultiOmics #MachineLearning #MendelianRandomization #Fluxomics #GenerativeAI #SpatialTranscriptomics #CatalyzingDay #DomainSpecific #FoundationModel #AgriculturalBiotechnology #ThreeTierFramework #TranslationalPipeline*

---

### Post 8: 오늘의 요약 — Catalyzing(Catalyzing Day) 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

8/13(Catalyzing)의 핵심: Consolidating(8/12)된 기술들이 서로를 catalyst로 삼아 **다음 단계의 연쇄 반응을 시작**하는 날이었다.

**1. 뇌혈관세포 Atlas(Cell 2026)**: 314,535 transcriptome + 1,529,740 cells spatial mapping → VCEs discovered → small vessel disease + stroke 치료 타겟 발견의 표준 catalyst. [Wang Cell 2026]

**2. ALDH9A1 NSCLC multi-omics(PNAS 2026)**: CODEX+metabolomics+CyTOF+ATAC-seq+spatial 통합 → ALDH9A1-carnitine axis → IL-1β feedback loop → anti-PD-1 resistance 돌파의 catalyst. [Du PNAS 2026]

**3. Cervical Cancer Spatial Immunity(Frontiers Immunology 2026)**: SPP1/C1QC macrophage + HPV-cGAS-STING circuits → spatial immune niche 모델 재정의 → 면역저항성 돌파 전략의 catalyst. [Huang Frontiers Immunology 2026]

**4. Prime Editing PE7 + NanoCas(BMB Reports 2026 + Molecular Biotechnology 2026)**: PE1→PE7 evolution + nanoCas delivery advantages → in vivo therapeutic applications의 연쇄 반응 catalyst. [Jong BMB Reports 2026; Hossain Molecular Biotechnology 2026]

**5. AI Competitive Docking(npj Drug Discovery 2026)**: Pairwise competitive docking + Boltz-2 integration → concordance 0.52~0.89 → de novo inhibitor design의 practical catalyst. [Mirgaux npj Drug Discovery 2026]

**6. Livestock Multi-Omics Framework(Advanced Science 2026)**: Three-tier causal inference framework → Mendelian randomization + fluxomics → precision breeding의 catalyst. [Wen Advanced Science 2026]

**8월 14일 전망**: Catalyzing된 기술들이 다음 단계에서 서로의 연쇄 반응을 가속화하는 속도가 핵심 변수. 특히 ALDH9A1 axis의 임상적 검증, nanoCas delivery의 in vivo 실증, pairwise competitive docking의 pharmaceutical industry 적용이 관전.

*출처: [Wang Cell 2026](https://www.cell.com/cell/abstract/S0092-8674(26)00805-6), [Du PNAS 2026](https://www.pnas.org/doi/10.1073/pnas.2535328123), [Huang Frontiers Immunology 2026](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1896004/full), [Jong BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/), [Hossain Molecular Biotechnology 2026](https://consensus.app/papers/details/9d5090d89fcc57f989ef3d82ec5d090a/), [Mirgaux npj Drug Discovery 2026](https://consensus.app/papers/details/645fe54721bb5cb8b226c81c539960bc/), [Wen Advanced Science 2026](https://consensus.app/papers/details/96e627a4cb495033b5aad44ee8b6cffa/)*

*#CatalyzingDay #Summary #Catalyzing #ChainReaction #CerebrovascularAtlas #Wang #Cell2026 #ALDH9A1 #Du #PNAS #CervicalCancer #Huang #FrontiersImmunology #PrimeEditing #Jong #NanoCas #Hossain #CompetitiveDocking #Mirgaux #LivestockMultiOmics #Wen #AdvancedScience #Catalyzing #Consolidation #Integration #Translational #PrecisionMedicine #BrainAtlas #Immunotherapy #SpatialOmics #DrugDiscovery*

---

## Sources

[1] [Wang et al. — Spatial atlas of the human brain vasculature reveals specialized cell ensembles. Cell 2026](https://www.cell.com/cell/abstract/S0092-8674(26)00805-6)
[2] [Du et al. — Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. PNAS 2026](https://www.pnas.org/doi/10.1073/pnas.2535328123)
[3] [Huang et al. — Spatially organized macrophage-T-cell crosstalk in cervical cancer: insights from single-cell and spatial omics. Frontiers in Immunology 2026](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1896004/full)
[4] [Jong et al. — Prime editing updates: technological evolution, methodological expansion, and delivery strategies for in vivo applications. BMB Reports 2026](https://consensus.app/papers/details/11216802c06153dca45549e3d4ff98f5/)
[5] [Hossain et al. — Prime Editing, CRISPR-Cas9, and NanoCas Genome Editing for Cancer Treatment. Molecular Biotechnology 2026](https://consensus.app/papers/details/9d5090d89fcc57f989ef3d82ec5d090a/)
[6] [Mirgaux et al. — AI-guided competitive docking for virtual screening and compound efficacy prediction. npj Drug Discovery 2026](https://consensus.app/papers/details/645fe54721bb5cb8b226c81c539960bc/)
[7] [Wen et al. — Livestock Multi-Omics Integration: A Systematic Framework From Statistical Association to Causal Interpretation. Advanced Science 2026](https://consensus.app/papers/details/96e627a4cb495033b5aad44ee8b6cffa/)